The two cities 100 yuan stock camp has changed, 36 pharmaceutical and biological stocks shortlisted

After the holiday, some changes have taken place in the 100-yuan stock camp in the two cities.
the new closing price, the average A-share price was 11.47 yuan at the close of trading on October 9, with 132 stocks trading above 100 yuan in two markets, according to Databo. Among the
stocks, Guizhou Maotaidan Daily closed up 1.65 percent at 1,696.00 yuan, followed by Gibbit, StoneTech and others, with new closing prices of 636.27 yuan and 612.50 yuan, respectively.
of the new 100 yuan shares, to Shenwan first-class industry classification, the more concentrated industries are pharmaceutical biology, electronics, computers and so on, of which, the pharmaceutical and biological industry has 36 stocks on the list, accounting for 27.27% of the total number of 100 yuan shares.
in the pharmaceutical and biological industry, Kanghua Bio performance is still relatively bright, the new closing price of 507.00 yuan, 9 up 2.21%, a change rate of 5.53%.
followed by Changchun Gaoxin and Meirui Medical, the new closing prices were 372.00 yuan and 358.10, respectively, up 0.64 percent, 2.90 percent, and the change rate reached 1.55 percent and 0.79 percent, respectively.
Kanghua Bio was founded in 2004, the main business includes the prevention of biological products production, sales, research, development and technical services, the existing products of secondary cell rabies vaccine and ACYW135 group meningococcal polysaccharide vaccine.
company recently released the first three quarters of 2020 results forecast, the first three quarters are expected to achieve the net profit attributable to shareholders of listed companies 325 million yuan - 355 million yuan, an increase of 267.37 percent - 301.28 percent year-on-year.
explained that the big increase in earnings was due to improved corporate fundamentals.
January-September Kanghua biological products freeze-dried human rabies vaccine (human double body cells) due to market demand and other factors, production and sales, to achieve high-speed growth.
, the company's management efficiency improved, the scale effect gradually appeared.
the results of the good news, Kanghua Bio's share price began to rise, 18 opened 10.98 percent higher, leading the bio-vaccine stocks.
industry believes that Kanghua Bio in the first three quarters of the net profit caused by the surge in the share price, is the price repair performance after the recent sharp fall in the share price, the impact on the late trend of the enterprise is limited.
, which is the second-largest stock, returns to the previous rally still needs to look at the development and breakthrough of the core technology, the sustainability of performance growth is still the key.
pharmaceutical and biological industry stocks, the biggest rise is Kantai Medical, as of October 9, Kantai Medical closed at 128.75 yuan, up 20.00%, turnover of 1.342 billion yuan, turnover rate of 29.18%.
was followed by C-Emmy and Zhifei Bio, up 8.41% and 7.67%, respectively.
also performed well, closing at 131.15 yuan, up 7.05 percent.
,2020 trading disclosure information shows that Kantai Medical is among the top five securities with a daily gain of 15%.
4,、、,、、、,5664.63,3424.97,2239.66。
data show that Kantai Medical Co., D.C.'s main business is blood oxygen, other, guardianship, 2020 mid-year report shows that the company achieved operating income of 751 million yuan, an increase of 421.17 percent year-on-year;
note that the company has not had an institutional rating in the past 180 days.